NRIX NASDAQ
Credit Risk of going bust: lower than 73% of companies Debt: 2.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.07 (down 99.7%), Nurix Therapeutics, Inc. would be worth roughly what it owes.
Total debt $65.3M against a stock market value of $2.79B.
Distance to default 8.06 (Merton model): prices to 2026-10-26, balance sheet 2026-08-31, debt counted $32.7M (short-term plus half of long-term), stock volatility 54.6%; Altman Z'' 9.83. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Brisbane, CA 94005
US
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Brutonâs tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hansen Gwenn | S-Sale | 1,452 | $25.00 | 2026-10-15 |
| GREGORY JULIA P | M-Exempt | 22,583 | $1.86 | 2026-10-14 |
| GREGORY JULIA P | S-Sale | 22,583 | $23.40 | 2026-10-14 |
| GREGORY JULIA P | M-Exempt | 22,583 | $1.86 | 2026-10-14 |
| Ring Christine | M-Exempt | 5,786 | $8.72 | 2026-10-02 |